NASDAQ: AARD

Aardvark Therapeutics, Inc. Common Stock

Healthcare | Biotechnology

$7.52 as of 2026-09-05 09:53 UTC

Market Cap$160M

Volume195.2K

EPS (TTM)$-2.93

Aardvark Therapeutics, Inc. Common Stock (NASDAQ: AARD) is a $160M biotechnology company trading at $7.52. Figures from SEC EDGAR and market feeds; updated 2026-09-05 09:53 UTC.

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Quote	09:53 UTC
Price	$7.52
Market cap	$160M
Volume	195.2K shares
Valuation	DEF 14A 2026-07-10
EPS (TTM)	$-2.93
Price/book	1.50×

Price Chart

Interactive chart available in terminalLive price charts with full OHLCV data, volume overlay, and technical indicators.
Open AARD in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-08-21

2026-08-21Baynes Roy D.A44,964—
2026-08-21Chi JeffreyA44,964—
2026-08-21Graf Susan EA44,964—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q1

Decheng Capital LLC3,917,299$14.77M0.0%
Cormorant Asset Management, LP800,189$10.82M0.0%
VANGUARD GROUP INC717,430$9.42M+29.1%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-06-12Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2026-02-12Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

AARD Stockholders Have Rights – If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
businesswire.com2026-09-04NEG
ROSEN, LEADING INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARD
newsfilecorp.com2026-09-04
AARD DEADLINE NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
newsfilecorp.com2026-09-04NEG
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action
prnewswire.com2026-09-03NEG
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aardvark Therapeutics, Inc. (AARD)
globenewswire.com2026-09-02NEG

Questions this page answers

What does Aardvark Therapeutics, Inc. Common Stock do?

Aardvark Therapeutics, Inc. Common Stock is a biotechnology company, listed on NASDAQ as AARD.

What is AARD's valuation?

AARD trades at $7.52, as of 2026-09-05.

When did AARD last file with the SEC?

Aardvark Therapeutics, Inc. Common Stock's most recent SEC filing on record is a DEF 14A filed 2026-07-10. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-09-05 09:53 UTC. This page is also available as JSON at /api/data?ticker=AARD and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for AARD and 5,000+ tickers.

Create a free account — keep AARD

For your agent

GET /api/data?ticker=AARD

This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt